Saturday 17 October 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 53.1%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
10.78
0.65
−5.69%
Follow BHVN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 | — | — | — | — |
P/S ratio |
— | — | — | — | 9.07 | 53.04 | — | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | — | (164.16) | 8.14 | — | — | — | — |
P/B ratio |
— | — | — | — | 156.42 | 0.00 | — | — | — | — |
Price to Tangible BV |
— | — | — | — | 364.16 | 0.00 | — | — | — | — |
EV/Sales |
— | — | — | — | 10.14 | 52.75 | — | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | — | (41.60) | (44.18) | — | — | — | — |
EV/FCF |
— | — | — | — | (36.22) | (27.93) | — | — | — | — |
Quick Ratio |
2.75 | 3.17 | 7.13 | 6.07 | 2.05 | 1.71 | 4.79 | 13.53 | 13.94 | 2.97 |
Current Ratio |
3.18 | 3.49 | 7.98 | 6.52 | 2.26 | 2.17 | 4.96 | 13.94 | 14.49 | 3.03 |
Net Debt/EBITDA |
0.11 | 0.55 | 0.89 | 0.83 | 0.34 | 0.77 | 0.14 | 0.66 | 1.22 | 0.38 |
Debt/Assets |
52.92% | 0.00% | 0.00% | 4.62% | 1.97% | 38.93% | 72.04% | 40.69% | 0.00% | 2.20% |
Debt/Equity |
4.59 | 0.00 | 0.00 | 0.06 | 0.08 | (0.68) | (33.41) | 0.78 | 0.00 | (0.34) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.69 | 0.81 | 0.52 | 0.68 | 0.64 | 0.71 | 0.82 | 0.68 | 0.46 |
Capex/Depreciation |
(0.07) | (0.47) | (0.44) | (4.38) | (0.67) | (613.85) | (5.86) | (0.96) | 0.00 | (5.20) |
Interest Coverage |
— | — | — | — | (1.63) | (1.34) | (12.19) | (19.15) | (118.74) | (157.50) |
| (310.75%) | (198.83%) | (84.44%) | (198.89%) | 119.61% | 59.39% | (737.03%) | (170.33%) | (320.22%) | 289.80% | |
| (138.54%) | (150.03%) | (69.48%) | (141.89%) | (51.58%) | (23.01%) | (166.74%) | (110.29%) | (160.08%) | (440.53%) | |
ROIC |
0.00% | 0.00% | (590.46%) | (515.93%) | 0.00% | 0.00% | 0.00% | (3,004.63%) | (13,367.54%) | 0.00% |
Return on Tangible Assets |
(275.31%) | (210.78%) | (100.98%) | (110.85%) | (324.43%) | (35.41%) | (195.67%) | (93.00%) | (107.42%) | (395.04%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.04 | 0.03 | 0.14 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.00 | (0.14) | — | — | — | — |
Graham Number |
— | — | — | — | 0.00 | 54.06 | — | — | — | — |
Earnings Yield |
— | — | — | — | (9.49%) | (15.21%) | — | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (3.09%) | (3.56%) | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(5.66) | (6.38) | (4.66) | (6.65) | (3.70) | (1.93) | (7.78) | (5.03) | (3.40) | (2.34) |
Capex per Share |
(0.01) | (0.04) | (0.04) | (0.14) | (0.02) | (1.12) | (0.08) | (0.11) | (0.02) | 0.00 |
Free Cash Flow per Share |
(5.67) | (6.42) | (4.70) | (6.79) | (3.73) | (3.05) | (7.86) | (5.14) | (3.42) | (2.34) |
Cash per Share |
2.97 | 5.33 | 5.36 | 11.19 | 1.93 | 9.02 | 6.53 | 6.74 | 4.72 | 1.87 |
Shareholders Equity per Share |
0.48 | 4.64 | 6.01 | 12.04 | 0.88 | (9.96) | (0.15) | 3.85 | 4.74 | (0.14) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.48 | 4.64 | 6.01 | 12.04 | 0.88 | (9.96) | (0.15) | 3.85 | 4.74 | (0.14) |
Free Cash Flow |
(610.15) | (586.11) | (334.77) | (303.76) | (146.78) | (120.15) | (381.11) | (201.31) | (95.36) | (29.53) |
Working Capital |
252.40 | 384.25 | 387.02 | 496.95 | 52.89 | 325.80 | 262.11 | 252.81 | 127.24 | 16.09 |
Capital Expenditures |
(0.71) | (3.66) | (3.05) | (6.07) | (0.94) | (44.20) | (3.78) | (4.16) | (0.54) | (0.03) |
Net Current Asset Value |
(31.05) | 346.80 | 357.21 | 463.96 | (12.55) | (475.76) | (23.41) | 133.25 | 121.75 | (4.74) |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 0.45 | 0.40 | 0.08 | 0.11 | 0.01 | 0.08 | 0.70 | 0.00 | 0.19 |
Cash ROIC |
(100.01%) | (64.45%) | (41.34%) | (28.39%) | (129.27%) | (52.10%) | (68.39%) | (37.76%) | (36.20%) | (131.85%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 7.92 | 29.70 | 28.03 | 65.01 | 214.00 | — | — | — | — |
Average Payables |
14.84 | 16.80 | 13.14 | 7.74 | 26.63 | 31.27 | 12.41 | 7.74 | 2.73 | 0.41 |
Average Inventory |
— | — | — | — | 60.09 | 60.50 | — | — | — | — |
Average Assets |
533.28 | 564.16 | 587.50 | 401.92 | 414.52 | 515.62 | 317.14 | 218.45 | 86.95 | 14.45 |
Average Common Equity |
237.75 | 425.71 | 483.37 | 286.73 | (178.75) | (199.81) | 71.75 | 141.45 | 43.47 | (21.97) |
Columns are period end dates